anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Patients hospitalized with COVID-19 may develop a hyperinflammatory, dysregulated cytokine "storm" that rapidly progresses to acute respiratory distress syndrome, multiple organ dysfunction, and even death. Remote ischaemic conditioning (RIC) has elicited anti-inflammatory and cytoprotective benefits by reducing cytokines following sepsis in animal studies. Therefore, we investigated whether RIC would mitigate the inflammatory cytokine cascade induced by COVID-19.
METHODS: We conducted a prospective, multicentre, randomized, sham-controlled, single-blind trial in Brazil and South Africa. Non-critically ill adult patients with COVID-19 pneumonia were randomly allocated (1:1) to receive either RIC (intermittent ischaemia/reperfusion applied through four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood-pressure cuff) or sham for approximately 15 days. Serum was collected following RIC/sham administration and analyzed for inflammatory cytokines using flow cytometry. The endpoint was the change in serum cytokine concentrations. Participants were followed for 30 days.
RESULTS: Eighty randomized participants (40 RIC and 40 sham) completed the trial. Baseline characteristics according to trial intervention were overall balanced. Despite downward trajectories of all cytokines across hospitalization, we observed no substantial changes in cytokine concentrations after successive days of RIC. Time to clinical improvement was similar in both groups (HR 1.66; 95% CI, 0.938-2.948, p 0.08). Overall RIC did not demonstrate a significant impact on the composite outcome of all-cause death or clinical deterioration (HR 1.19; 95% CI, 0.616-2.295, p = 0.61).
CONCLUSION: RIC did not reduce the hypercytokinaemia induced by COVID-19 or prevent clinical deterioration to critical care.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04699227.
Oxidative stress is tightly associated with liver dysfunction and injury in dairy cows. Previous studies have shown that cis-9, trans-11 conjugated linoleic acid (CLA) possesses anti-inflammatory and antioxidative abilities. In this study, the bovine hepatocytes were pretreated with CLA for 6 h, followed by treatment with hydrogen peroxide (H2O2) for another 6 h to investigate the antioxidative effect of CLA and uncover the underlying mechanisms. The results demonstrated that H2O2 treatment elevated the level of mitophagy, promoted mitochondrial DNA (mtDNA) leakage into the cytosol, and activated the stimulator of interferon genes (STING)/nuclear factor kappa B (NF-κB) signaling pathway to trigger an inflammatory response in bovine hepatocytes. In addition, the dynamin-related protein 1(DRP1)-mtDNA-STING-NF-κB axis contributed to the H2O2-induced oxidative injury of bovine hepatocytes. CLA could reduce mitophagy and the inflammatory response to attenuate oxidative damage via the DRP1/mtDNA/STING pathway in bovine hepatocytes. These findings offer a theoretical foundation for the hepatoprotective effect of CLA against oxidative injury in dairy cows.
Proposed are concepts for generating and using a prediction model that enables the prediction of the quality (e.g. accuracy and/or reliability) of an electrode configuration (i.e. arrangement) for electrophysiological measurements. It is proposed to use training data to determine parameter values of a prediction model so that the prediction model is configured to accurately predict a quality value (e.g. measure of accuracy) of an arrangement or pattern of electrodes for electrophysiological measurements of a subject. Embodiments may thus facilitate the assessment of an electrode configuration and/or there commendation of changes to an electrode configuration so as to enable more reliable and/or accurate electrophysiological measurements to be obtained.
OBJECTIVE: Intracranial electroencephalogram (iEEG) signals are generally recorded using multiple channels, and channel selection is therefore a significant means in studying iEEG-based seizure prediction. For n channels, [Formula: see text] channel cases can be generated for selection. However, by this means, an increase in n can cause an exponential increase in computational consumption, which may result in a failure of channel selection when n is too large. Hence, it is necessary to explore reasonable channel selection strategies under the premise of controlling computational consumption and ensuring high classification accuracy. Given this, we propose a novel method of channel reordering strategy combined with dual CNN-LSTM for effectively predicting seizures.
METHOD: First, for each patient with n channels, interictal and preictal iEEG samples from each single channel are input into the CNN-LSTM model for classification. Then, the F1-score of each single channel is calculated, and the channels are reordered in descending order according to the size of F1-scores (channel reordering strategy). Next, iEEG signals with an increasing number of channels are successively fed into the CNN-LSTM model for classification again. Finally, according to the classification results from n channel cases, the channel case with the highest classification rate is selected.
RESULTS: Our method is evaluated on the three iEEG datasets: the Freiburg, the SWEC-ETHZ and the American Epilepsy Society Seizure Prediction Challenge (AES-SPC). At the event-based level, the sensitivities of 100%, 100% and 90.5%, and the false prediction rates (FPRs) of 0.10/h, 0/h and 0.47/h, are achieved for the three datasets, respectively. Moreover, compared to an unspecific random predictor, our method also shows a better performance for all patients and dogs from the three datasets. At the segment-based level, the sensitivities-specificities-accuracies-AUCs of 88.1%-94.0%-93.5%-0.9101, 99.1%-99.7%-99.6%-0.9935, and 69.2%-79.9%-78.2%-0.7373, are attained for the three datasets, respectively.
CONCLUSION: Our method can effectively predict seizures and address the challenge of an excessive number of channels during channel selection.
The present disclosure relates to an infusion product for making a beverage, such as a tea or tea-like drink. In order to produce the composition of the present disclosure, plant materials are contacted with a solvent to remove an extract. The remaining plant materials are then formed into a fibrous structure or network, such as a sheet or fibrous layer. The extract may be further treated or concentrated and then reapplied to the plant materials. In accordance with the present disclosure, the resulting sheet or layer is then reduced to discrete pieces having a unique particle size distribution. Through the process of the present disclosure, a composition is produced that not only has a minimal amount of fines and dust, but can also have a relatively low bulk density.
Participants will consume a placebo consisting of maltodextrin each day for 6 weeks while completing the exercise training program. The placebo will be provided in capsule identical in appearance to the active supplement. On days that participants exercise, they will consume the placebo 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking.
Embodiments of the present disclosure provide an image processing method, an image processing device, and a medical imaging device. The image processing method includes acquiring color image data, and generating grayscale image data based on the color image data. Luminance of a grayscale image represented by the grayscale image data is equivalent to luminance of a color image represented by the color image data. The image processing device includes an image acquisition unit configured to acquire color image data, and a processor configured to generate grayscale image data based on the color image data. The medical imaging device includes the image processing device described above, and a displayer configured to display an image according to the image data generated by the image processing device. Embodiments of the present disclosure may conveniently convert a color image into a grayscale image and improve display definition of the medical imaging device.
Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain a sustained release medicinal preparation comprising fine granules produced by coating an active ingredient with a mixture of ethyl cellulose with eudoragit RS, not dissolved in gastric juice, intestinal juice, etc., capable of being swollen with the juices to permit the penetration of the juices without relating to the pHs of the juices. CONSTITUTION: This sustained release medicinal preparation comprises fine granules containing an active ingredient and coated with a mixture of ethyl cellulose with eudoragit RS (preferably the mixture of 60-40wt.%, especially 45wt.%, of ethyl cellulose with 40-60wt.%, especially 55wt.%, of eudoragit RS), and can control the dissolution of the active ingredient without relating to pHs. The coating mixture may further be mixed with a plasticizer (e.g. acetylated monoglyceride), and the fine granules comprise the active ingredient (e.g. diltiazem hydrochloride), preferably a diluent (e.g. fine crystalline cellulose) and preferably a binder (e.g. carboxymethyl cellulose). The sustained release medicinal preparation can release the active ingredient over the whole lengths of the stomach and the intestines.
Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azythromycin for 3 days beginning 14 days after after administration of the challenge strain.
PROBLEM TO BE SOLVED: To obtain a tablet capable of protecting a bacterium useful for the intestines during the production and ingestion periods, and delivering the bacterium to the intestines while keeping its activity by containing capsules in which the bacterium is encapsulated. SOLUTION: This tablet is obtained by mixing capsules, preferably soluble in the intestines, encapsulating a bacterium useful for the intestines (e.g. Bifidobacterium or acidophilus) with an excipient normally used for making food tablets, where the bacterium is suspended in a hardened oil (e.g. hardened palm or palm kernel oil) and encapsulating in the capsule shell. It is preferable to encapsule 20 to 50 pts.wt. of the bacterium per 100 pts.wt. of the suspension. The capsule shell to encapsule the suspension has an external and internal shells, the internal shell serving as the intermediate layer between the external shell and suspension, and preventing the bacterium from coming into contact with air, moisture or the like to protect it, whereas the external shell sealing the suspension and internal shell.
In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
The current proposal explores the use of a novel imaging modality, FLT PET/MRI, to correlate allogeneic transplant outcomes with FLT and MRI findings during early stem cell engraftment and at a later time point following stable count recovery. Specifically, this study will determine if the strength of the early FLT signal within the bone marrow correlates with engraftment success and if isolated areas of cellular proliferation within the marrow at a later time point might predict for leukemia relapse. In addition, based on the important role that host lymphoid tissues are known to play in GVHD pathogenesis in mice, this study will determine if the FLT signal within host SLT after transplant can predict for the development of GVHD in human BMT patients. Because FLT imaging by itself cannot distinguish between bone marrow engraftment/proliferation and the allo-immune driven T cell expansion that ultimately results in GVHD, this study will image autologous transplant patients as a comparator arm. Autologous HSCT like allogeneic transplantation involves the administration of very high doses of chemotherapy to high risk cancer patients in order to achieve better tumor kill. However, in this situation patients are administered their own cryopreserved stem cells to reconstitute the ablated hematopoietic system. Under those circumstances there is no allo-immune reactivity to drive T cell activation and expansion after transplant, and as a result there is no GVHD in the autologous transplant setting. Thus, these patients will help us to elucidate how much of the FLT signal seen in the allogeneic setting is the result of allo-immune driven T cell expansion.
Influenza viruses are one of the main pathogens that cause respiratory diseases affecting millions of people around the world, having a high percentage of morbidity and mortality. These viruses can be controlled by vaccination and antivirals. Regarding the latter, only two main types of antivirals are approved by the FDA: 1) inhibitors of the M2 ion channel and 2) Neuraminidase inhibitors. However, the rapid resistance emergence limits its effectiveness. Due to this, the search for structural compounds and novel activity against these viruses has been spread. Naphthoquinones represent an excellent study group, since a lot of activities have been reported: antibacterial, antifungal, anti-inflammatory, anticarcinogenic and antiviral; despite this, the anti-influenza activity is practically unexplored. In the present invention, the use of a dimeric naphthoquinone and its derivatives is described for the treatment and prevention of viral infections caused by viruses of the Ortomixoviridae family, particularly the influenza virus, presenting in its anti-influenza activity, a different mechanism to the neuraminidase inhibitors.
The adapted form of the MSC, composed for 12 sessions, will be delivered on a weekly basis in group. This intervention program intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind, courageous, and fierce way. All the sessions will be delivered in a space on each YDC.
The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
This article describes the case of a 40-year-old individual who presented with fulminant myocarditis. Initial ECG displayed sinus tachycardia with a heart rate of 117 bpm, QS complexes in leads V1-V3, ST-segment depression in leads II, III, aVF, V5-V6, and ST-segment elevation >0.2 mV in leads V1 through V3. The initial clinical assessment suggested an acute anteroseptal myocardial infarction. However, subsequent diagnostic evaluation through coronary angiography disclosed that the coronary arteries were normal. Therefore, clinicians should carefully consider the differential diagnosis between these conditions, as their management strategies differ markedly. Two hours after admission, the patient unexpectedly developed syncope. The ECG findings were consistent with the typical characteristics of bidirectional ventricular tachycardia. Our report described the appearance and morphology as well as mechanism of bidirectional ventricular tachycardia in detail. Additionally, we delineate differential diagnoses for disease that can cause bidirectional ventricular tachycardia, such as aconite poisoning, digoxin overdose, immune checkpoint inhibitor (ICI), myocardial ischemia, and hereditary channelopathies, such as catecholaminergic polymorphic ventricular tachycardia (CPVT) and Andersen-Tawil syndrome. Therefore, clinicians should recognize this ECG finding immediately and initiate appropriate treatment promptly as these measures may be vital in saving the patient's life.
Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
Benzonatate is chemically related to anesthetic agents of the para-aminobenzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Information for patients: Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. Therefore, the capsules should be swallowed without chewing.

Usage in Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with benzonatate capsules USP. It is also not known whether benzonatate capsules USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate capsules USP should be given to a pregnant woman only if clearly needed.

Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate capsules USP are administered to a nursing woman.

Carcinogenesis, mutagenesis, impairment of fertility: Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate capsules USP.

Pediatric Use: Safety and effectiveness in children below the age of 10 have not been established.
The invention discloses a herbal menthae ingredient particle and a preparation method and a quality control method thereof. The ingredient particle uses the herbal menthae as raw materials. The herbal menthae is processed by quantitative extraction and quantitative volatile oil is added. The herbal methae and the volatile oils are processed by water extraction, inclusion and spray drying, and the like, to obtain spray drying herbal menthae powder. The herbal menthae ingredient particle is prepared by the spray drying herbal menthae powder directly or by the spraying drying herbal menthae powder and the auxiliary materials with proper amount. Every gram of the herva menthae ingredient particle of the invention is provided with an IR fingerprint spectra indicated as a Fig3. The preparation method of the invention adopts the quantitative equivalent extracting addition method of the volatile oil so as to ensure drug effect and reduce toxicity and side effects. The technology of the IR fingerprint spectra is adopted by the invention for quality control and the quality control method is scientific, advanced, quick and highly feasible.
As with all AEDs, VIGPODER should be withdrawn gradually. However, if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. Patients and caregivers should be told not to suddenly discontinue VIGPODER therapy.

In controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by decreasing the daily dose 1000 mg/day on a weekly basis until discontinued.

In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered by decreasing the daily dose by one third every week for three weeks.

In a controlled clinical study in patients with infantile spasms, vigabatrin was tapered by decreasing the daily dose at a rate of 25 to 50 mg/kg every 3 to 4 days.
Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
OBJECTIVE: This study was conducted to investigate the validity and reliability of the Turkish version of the Premenstrual Change Coping Inventory (PMS-Cope).
METHODS: A total of 170 women who met the inclusion criteria were included in the methodological study. Data were collected between the dates of November 5, 2018 and May 5, 2019 with personal information form, PMS-Cope Turkish version, and Premenstrual Syndrome Scale.
RESULTS: The PMS-Cope was obtained through the translation-back translation method and the content validity was obtained according to expert opinions. After the factor analysis, the Turkish version of the PMS-Cope consisted of three sub-dimensions as in the original scale. The factor loadings of the three-dimensional scale ranged from 0.46 to 0.84, and the explained variance (60.329%) was at the desired level. As a result of structural equation modeling; ×2/SD values of the scale were found to be 4.19, GFI 0.93, AGFI 0.91, CFI 0.95, RMSEA 0.079, and SRMR 0.082, and this scale was acceptable. The Cronbach alpha coefficient of the PMS-Cope was 0.86. It was determined that item-total score correlations were higher than 0.30 in all items of PMS-Cope and there was no need to remove items from the scale. When the mean scores of the lower 27% and upper 27% of the scale were compared, a statistically significant difference was found between the groups (p < 0.05). The PMS-Cope score was 41.04 ± 8.99.
CONCLUSION: It was determined that the Turkish version of the PMS-Cope was a valid and reliable measurement tool.
Eligible subjects randomized to Arm 1 will receive an intravenous (IV) infusion of OTL-203 gene therapy. Subjects will receive conditioning regimen with busulfan and fludarabine prior to OTL-203 infusion.
Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
BACKGROUND AND PURPOSE: Cerebral vasospasm is a common complication of aneurysmal SAH and remains a risk factor for delayed cerebral ischemia and poor outcome. The interrater reliability of CTA in combination with CTP has not been sufficiently studied. We aimed to investigate the reliability of CTA alone and in combination with CTP in the detection of cerebral vasospasm and the decision to initiate endovascular treatment.
MATERIALS AND METHODS: This is a retrospective single-center study including patients treated for aneurysmal SAH. Inclusion criteria were a baseline CTA and follow-up imaging including CTP due to suspected vasospasm. Three neuroradiologists were asked to grade 15 intracranial arterial segments in 71 cases using a tripartite scale (no, mild <50%, or severe >50% vasospasm). Raters further evaluated whether endovascular treatment should be indicated. The ratings were performed in 2 stages with a minimum interval of 6 weeks. The first rating included only CTA images, whereas the second rating additionally encompassed CTP images. All raters were blinded to any clinical information of the patients.
RESULTS: Interrater reliability for per-segment analysis of vessels was highly variable (κ = 0.16-0.61). We observed a tendency toward higher interrater reliability in proximal vessel segments, except for the ICA. CTP did not improve the reliability for the per-segment analysis. When focusing on senior raters, the addition of CTP images resulted in higher interrater reliability for severe vasospasm (κ = 0.28; 95% CI, 0.10-0.46 versus κ = 0.46; 95% CI, 0.26-0.66) and subsequently higher concordance (κ = 0.23; 95% CI, -0.01-0.46 versus κ = 0.73; 95% CI, 0.55-0.91) for the decision of whether endovascular treatment was indicated.
CONCLUSIONS: CTA alone offers only low interrater reliability in the graduation of cerebral vasospasm. However, using CTA in combination with CTP might help, especially senior neuroradiologists, to increase the interrater reliability to identify severe vasospasm following aneurysmal SAH and to increase the reliability regarding endovascular treatment decisions.